Ocrevus 300 mg concentrate for solution for infusion [Ocrelizumab] , Ocrevus 920 mg solution for injection [Ocrelizumab] clinical trials

A study to find out the best length of time between ocrelizumab doses for patients with relapsing remitting multiple sclerosis using a trial design with multiple groups and multiple stages

This study looks at how often people with a type of MS called relapsing-remitting MS should take their ocrelizumab medicine. Researchers want to find the best dosing schedule to help manage their symptoms effectively, by trying different timings between doses.